TGFBR1 and lymphoid neoplasm: Since we saw overlapping impairments in the MSCs of various entities, particularly in osteogenic differentiation, we induced osteogenic differentiation in healthy MSCs and in MSCs derived from myeloid and lymphoid neoplasms, and added the active ATP-competitive transforming growth factor-β receptor 1 (TGF-βRI) (ALK5) inhibitor SD208 to each medium change within the osteogenic differentiation period.